1. Mayro, B.; Hoj, J.P.; Cerda-Smith, C.G.; Hutchinson, H.M.; Caminear, M.W.; Thrash, H.L.; Winter, P.S.; Wardell, S.E.; McDonnell, D.P.; Wu, C.; Wood, K.C.; Pendergast, A.M.* (2023). ABL kinases regulate the stabilization of HIF-1a and MYC through CPSF1, ProcNatl. Acad. Sci. USA 120, e2210418120.
  2. Killarney, S.T.; Washart, R.; Soderquist, R.S.; Hoj, J.P.; Lebhar, J.; Lin, K.H.; Wood, K.C.* (2023). Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis, Nature Communications 14, 1399. [Pubmed][PDF]
  3. Lidsky, M.E. ¶,*; Wang, Z.; Lu, M.; Liu, A.; Hsu, S.D.; McCall, S.J.; Sheng, Z.; Granek, J.A.; Owzar, K.; Anderson, K.S.; Wood, K.C.* (2022). Leveraging unique patient-derived models of FGFR2 fusion-positive intrahepatic cholangiocarcinoma to identify novel synergistic therapies, npj Precision Oncology 6, 75. [Pubmed][PDF] (¶Co-first authors; *Co-corresponding authors).
  4. Kishton, R.J.*; Patel, S.J.; Decker, A.E.; Vodnala, S.K.; Cam, M.; Yamamoto, T.N.; Patel, Y.; Sukumar, M.; Yu, Z.; Ji, M.; Henning, A.N.; Gurusamy, D.; Palmer, D.C.; Stefanescu, R.A.; Girvin, A.T.; Lo, W.; Pasetto, A.; Malekzadeh, P.; Deniger, D.C.; Wood, K.C.; Sanjana, N.E.; Restifo, N.P.* (2022). Cancer genes disfavoring T cell immunity identified via integrated systems approach, Cell Reports 40, 111153. [Pubmed][PDF]
  5. Lin, K.H.; Rutter, J.C.; Xie, A.; Killarney, S.T.; Vaganay, C.; Benaksas, C.; Ling, F.; Sodaro, G.; Meslin, P.A.; Bassil, C.F.; Fenouille, N.; Hoj, J.P.; Washart, R.; Ang, H.X.; Cerda-Smith, C.G.; Chaintreuil, P.; Jacquel, A.; Auberger, P.; Forget, A.; Itzykson, R.; Lu, M.; Lin, J.; Pierobon, M.; Sheng, Z.; Li, X.; Chilkoti, A.; Owzar, K.; Rizzieri, D.A.; Pardee, T.S.; Benajiba, L.; Petricoin, E.; Puissant, A.*; Wood, K.C.* (2022). P2RY2-AKT activation is a critical actionable consequence of nuclear export inhibition in acute myeloid leukemia, Nature Cancer 3, 837-851. (¶Co-first authors; *Co-corresponding authors). [Pubmed][PDF]
  6. Ali, M.; Lu, M.; Ang., H.X.; Soderquist, R.S.; Eyler, C.E.; Hutchinson, H.M.; Glass, C.; Bassil, C.F.; Lopez, O.M.; Kerr, D.L.; Falcon, C.J.; Yu, H.A.; Hata, A.N.; Blakely, C.M.; McCoach, C.E.; Bivona, T.G.; Wood, K.C. (2022). Small molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells, Science Translational Medicine 14, eabc7480. [Pubmed][PDF]
  7. Zhong, Z.; Harmston, N.; Wood, K.C.; Madan, B.; Virshup, D.M.* (2022). A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models, J. Clin. Inv. 132, e156305. [Pubmed][PDF]
  8. Javaid, S.; Schaefer, A.; Goodwin, C.M.; Nguyen, V.V.; Massey, F.L.; Pierobon, M.; Gambrell-Sanders, D.; Waters, A.M.; Lambert, K.N.; Hobbs, A.G.; Huynh, M.V.; Wood, K.C.; Petricoin, E.F.; Der, C.J.; Cox, A.D.* (2022). Concurrent ERK inhibition blocks farnesyltransferase inhibitor-induced epithelial-to-mesenchymal transition to suppress the growth of HRAS mutant head and neck squamous cell carcinoma, Mol. Cancer Ther. (In press). [Pubmed]
  9. Garcia, N.; Del Pozo, V.; Yohe, M.E.; Goodwin, C.M.; Shackleford, T.J.; Wang, L.; Baxi, K.; Chen, Y.; Rogojina, A.T.; Zimmerman, S.M.; Peer, C.J.; Figg, W.D.; Ignatius, M.S.; Wood, K.C.; Houghton, P.J.; Vaseva, A.V.* (2021). Vertical inhibition of the RAF-MEK-ERK cascade induces myogenic differentiation, apoptosis, and tumor regression in H/NRAS Q61X-mutant rhabdomyosarcoma, Mol. Cancer Ther. (In press). [Pubmed][PDF]
  10. Luttman, J.H.; Hoj, J.P.; Lin, K.H.; Lin, J.; Gu, J.J.; Rouse, C.; Nichols, A.G.; MacIver, N.J.; Wood, K.C.; Pendergast, A.M.* (2021). ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells, Cell Reports 37, 109880. [Pubmed][PDF]
  11. Yellen, B.B.*; Zawistowski, J.S.; Czech, E.A.; Sanford, C.I.; SoRelle, E.D.; Luftig, M.A.; Forbes, Z.G.; Wood, K.C.*; Hammerbacher, J.* (2021) Massively parallel quantification of phenotypic heterogeneity in single cell drug responses, Science Advances 7, eabf9840. (*Co-corresponding authors) [Pubmed][PDF]
  12. Joh, D.Y.; Heggestad, J.T.; Zhang, S.; Anderson, G.R.; Bhattacharyya, J.; Wardell, S.E.; Wall, S.A.; Cheng, A.B.; Albarghouthi, F.; Liu, J.; Oshima, S.; Hucknall, A.M.; Hyslop; Hall, A.H.S.; Wood, K.C.; Hwang, E.S.; Strickland, K.C.; Wei, Q.*; Chilkoti, A.* (2021) Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates, npj Breast Cancer (In press) (Co-first authors; *Co-senior authors).
  13. Su, A.; Ling, F.; Vaganay, C.; Sodaro, G.; Benaksas, C.; Del Bello, R.; Forget, A.; Benajiba, L.; Pardieu, B.; Lin, K.H.; Rutter, J.C.; Bassil, C.F.; Fortin, G.; Pasanisi, J.; Antony-Debre, I.; Alexe, G.; Benoist, J.-F.; Pruvost, A.; Pikman, Y.; Qi, J.; Schlageter, M.H.; Micol, J.B.; Roti, G.; Cluzeau, T.; Dombret, H.; Preudhomme, C.; Fenouille, N.; Golan, H.M.; Stegmaier, K.; Lobry, C.*; Wood, K.C.*; Itzykson, R.*; Puissant, A.* (2020). The folate cycle enzyme MTHFR is a critical regulator of cell response to MYC-targeting therapies, Cancer Discovery 10, 1894-1911. (Co-first authors; *Co-senior authors) [Pubmed][PDF]
  14. Ozkan-Dagliyan, I.; Diehl, J.N.; George, S.D.; Schaefer, A.; Papke, B.; Klotz-Noack, K.; Waters, A.M.; Goodwin, C.M.; Gautam, P.; Pierobon, M.; Peng, S.; Gilbert, T.S.K.; Lin, K.H.; Dagliyan, O.; Wennerberg, K.; Petricoin, E.F.; Tran, N.L.; Bhagwat, S.V.; Tiu, R.V.; Peng, S.B.; Herring, L.E.; Graves, L.M.; Sers, C.; Wood, K.C.; Cox, A.D.; Der, C.J. (2020). Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers, Cell Reports 31, 107764. [PDF][Pubmed]
  15. Lin, K.H.; Rutter, J.C.; Xie, A.; Pardieu, B.; Winn. E.T.; Dal Bello, R.; Forget, A.; Itzykson, R.; Ahn, Y.-R.; Dai, Z.; Sobhan, R.T.; Anderson, G.R.; Singleton, K.R.; Decker, A.E.; Winter, P.S.; Locasale, J.W.; Crawford, L.; Puissant, A.*; Wood, K.C.* (2020). Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer, Nature Genetics 52, 408-417. (co-first authors; *co-corresponding authors) [PDF][Pubmed]
  16. Liberti, M.V.; Allen, A.; Singleton, K.R.; Guo, Z.; Liu, J.O.; Wood, K.C.; Locasale, J.W. (2020). Evolved resistance to partial GAPDH inhibition results in loss of the Warburg Effect and in a different state of glycolysis, J Biol Chem 295, 111-124. [Pubmed][PDF]
  17. Manzari, M.T.; Anderson, G.R.; Lin, K.H.; Soderquist, R.S.; Cakir, M.; Zhang, M.; Moore, C.E.; Skelton, R.N.; Fevre, M.; Li, X.; Bellucci, J.J.; Wardell, S.E.; Costa, S.A.; Wood, K.C.*; Chilkoti, A.* (2019). Genomically informed small molecule drugs overcome resistance to a sustained release formulation of an engineered death receptor agonist in patient-derived tumor models, Science Advances 5, eaaw9162. (*Co-corresponding authors) [PDF][Pubmed]
  18. Zhong, Z.; Sepramaniam, S.; Chew, X.H.; Wood, K.; Lee, M.A.; Madan, B.; Virshup, D.M. (2019). PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers, Oncogene 38, 6662. [PDF][Pubmed]
  19. Cakir, M.; Mukherjee, S.; Wood, K.C. (2019). Label propagation defines signaling networks associated with recurrently mutated cancer genes, Sci. Rep. 9, 9104. [PDF][Pubmed]
  20. Armstrong, A.J.; Gupta, S.; Healy, P.; Kemeny, G.; Leith, L.; Zalutsky, M.R.; Spritzer, C.; Davies, C.; Rothwell, C.J.; Ware, K.E.; Somarelli, J.; Wood, K.; Riber, T.; Giannakakou, P.; Zhang, J.; Gerber, D.; Anand, M.; Foo, W.-C.; Halabi, S.; Gregory, S.G.; George, D.J. (2019) Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer, PLoS ONE 14, e0216934. [PDF][Pubmed]
  21. Lin, K.H.; Xie, A.; Rutter, J.C.; Ahn, Y.; Lloyd-Cowden, J.M.; Nichols, A.G.; Soderquist, R.S.; Koves, T.R.; Muoio, D.; MacIver, N.J.; Lamba, J.; Pardee, T.S.; McCall, C.M.; Rizzieri, D.A.; Wood, K.C. (2019). Systematic dissection of the metabolic-apoptotic interface in AML reveals heme biosynthesis to be a regulator of drug sensitivity, Cell Metabolism 29, 1217. (Co-first authors; journal cover article) [PDF][Pubmed]
  22. Ding, Y.; Huang, D.; Chen, R.; Gong, C.; Sui, P.; Lin, K.H.; Yuan, L.; Xiang, H.; Chen, J.; Yin, T.; Wang, Q.F.; Alexander, P.D.; Song, E.W.; Li, Q.-J.; Wood, K.C.*; Wang, X.F.* (2018). Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers, Nature Communications 9, 4274. (*Co-corresponding authors) [PDF][Pubmed]
  23. Soderquist, R.S.; Crawford, L.; Liu, E.; Lu, M.; Agarwal, A.; Anderson, G.R.; Lin, K.H.; Winter, P.S.; Cakir, M.; Wood, K.C. (2018). Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity, Nature Communications 9, 3513. [PDF][Pubmed]
  24. Ohiri, K.A.; Kelly, S.T.; Motschman, J.D.; Lin, K.H.; Wood, K.C.; Yellen, B.B. (2018). A high throughput bulk acoustic wave device for the capture and compartmentalization of single cells, Lab on a Chip 18, 2124-2133. [PDF][Pubmed]
  25. Anderson, G.R.; Wardell, S.E.; Cakir, M.; Yip, C.; Ahn, Y.; Ali, M.; Yllanes, A.P.; Chao, C.A.; McDonnell, D.P.; Wood, K.C. (2018). Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors, Nature Communications 9, 1677. [PDF][Pubmed]
  26. Crawford, L.A.; Wood, K.C.; Zhou, X.; Mukherjee, S. (2018). Bayesian approximate kernel regression with variable selection, J. Am. Stat. Assoc113, 1710-1721. [PDF][Link]
  27. Singleton, K.R.; Crawford, L.; Tsui, E.; Manchester, H.E.; Maertens, O.; Liu, X.; Liberti, M.V.; Magpusao, A.N.; Stein, E.M.; Tingley, J.P.; Frederick, D.T.; Boland, G.M.; Flaherty, K.T.; McCall, S.J.; Krepler, C.; Sproesser, K.; Herlyn, M.; Adams, D.J.; Locasale, J.W.; Cichowski, K.; Mukherjee, S.; Wood, K.C. (2017). Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence, Cell Reports 21, 2796-2812. (Co-first authors) [PDF][Pubmed]
  28. Anderson, G.R.¶; Winter, P.S.¶; Lin, K.H.; Nussbaum, D.P.; Cakir, M.; Stein, E.M.; Soderquist, R.; Crawford, L.; Leeds, J.C.; Newcomb, R.; Stepp, P.; Yip, C.; Wardell, S.E.; Tingley, J.P.; Ali, M.; Xu, M.; Ryan, M.; McCall, S.J.; McRee, A.; Counter, C.M.; Der, C.J.; Wood, K.C. (2017). A landscape of therapeutic cooperativity in KRAS mutant cancers reveals principles for controlling tumor evolution, Cell Reports 20, 999-1015. (¶Co-first authors) [PDF][Pubmed]
  29. Ali, M.¶; Kaltenbrun, E.¶; Anderson, G.R.¥; Stephens, S.J.¥; Arena, S.; Bardelli, A.; Counter, C.M.*; Wood, K.C.* (2017). Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance, Nature Communications 8, 15617. (¶Co-first authors, ¥Co-second authors, *Corresponding authors) [PDF] [PubMed]
  30. Price, A.M.; Dai, J.; Bazot, Q.; Patel, L.; Nikitin, P.A.; Djavadian, R.; Winter, P.S.; Salinas, C.A.; Perkins Barry, A.; Wood, K.C.; Johannsen, E.C.; Letai, A.; Allday, M.J.; Luftig, M.A. (2017). Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection, eLife 6, e22509. [PDF][Pubmed]
  31. Anderson, G.R.; Wardell, S.E.; Cakir, M.; Crawford, L.; Leeds, J.C.; Nussbaum, D.N.; Shankar, P.S.; Soderquist, R.S.; Stein, E.M.; Tingley, J.P.; Winter, P.S.; Zeiser-Misenheimer, E.K.; Alley, H.M.; Yllanes, A.; Haney, V.; Blackwell, K.L.; McCall, S.J.; McDonnell, D.P.; Wood, K.C. (2016). PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation, Science Translational Medicine 8, 369ra175. [PDF][Pubmed]
  32. Lin, K.H.; Winter, P.S.; Xie, A.; Roth, C.; Martz, C.A.; Stein, E.M.; Anderson, G.R.; Tingley, J.P.; Wood, K.C. (2016) Targeting MCL-1/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia Sci. Rep. 6, 27696. [PDF][Pubmed]
  33. Cribb, J.; Osborne, L.D.; Beicker, K.; Psioda, M.; Chen, J.; O’Brien, E.T.; Taylor II, R.M.; Vicci, L.; Hsiao, J.P.L.; Shao, C.; Falvo, M.; Ibrahim, J.G.; Wood, K.C.; Blobe, G.C.; Superfine, R. (2016). An Automated High-throughput Array Microscope for Cancer Cell Mechanics, Sci. Rep. 6, 27371. [PDF][Pubmed]
  34. Park, S.; Chang, C.; Safi, R.; Liu, X.; Baldi, R.; Jasper, J.; Anderson, G.; Liu, T.; Rathmell, J.; Dewhirst, M.W.; Wood, K.C.; Locasale, J.W.; McDonnell, D.P. (2016). ERRα regulated lactate metabolism contributes to resistance to targeted therapies in breast cancer, Cell Reports 15(2), 323-335. [PDF][Pubmed]
  35. Son, S.; Stevens, M.M.; Chao, H.X.; Thoreen, C.; Hosios, A.M.; Schweitzer, L.D.; Weng, Y.; Wood, K.; Sabatini, D.; Vander Heiden, M.G.; Manalis, S. (2015). Cooperative nutrient accumulation sustains growth of mammalian cells, Sci. Rep. 5, 17401. [PDF] [Pubmed]
  36. Misale, S.; Bozic, I.; Tong, J.; Peraza-Penton, A.; Lallo, A.; Baldi, F.; Lin, K.H.; Di Nicolantonio, F.; Nowak, M.A.; Zhang, L.; Wood, K.C.; Bardelli, A. (2015). Vertical suppression of the EGFR pathway delays onset of resistance in colorectal cancer models, Nature Communications 6, 8305-14. [PDF] [Pubmed]
  37. Martz, C.A.¶; Ottina, K.A.¶; Singleton, K.S.¶; Jasper, J.S.; Wardell, S.E.; Peraza-Penton, A.; Anderson, G.R.; Winter, P.S.; Wang, T.; Alley, H.M.; Kwong, L.N.; Cooper, Z.A.; Tetzlaff, M.; Chen, P.-L.; Rathmell, J.C.; Flaherty, K.T.; Wargo, J.A.; McDonnell, D.M.; Sabatini, D. M.*; Wood, K.C.* (2014). Systematic identification of signaling pathways with potential to confer anticancer drug resistance, Science Signaling 7, ra121. (¶Co-first authors, *Co-corresponding authors; journal cover article) [PDF] [Pubmed] [Podcast] [Table S3]
  38. Winter, P.S.; Sarosiek, K.A.; Lin, K.H.; Meggendorfer, M.; Schnittger, S.; Letai, A.; Wood, K.C. (2014). RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis, Science Signaling 7, ra122. [PDF] [Pubmed] [Podcast] [Table S4]
  39. Gerriets, V.A.; Kishton, R.J.; Nichols, A.G.; Macintyre, A.N.; Inoue, M.; Ilkayeva, O.; Winter, P.S.; Wood, K.C.; Liu, X.; Priyadharshini, B.; Slawinska, M.E.; Haeberli, L.; Huck, C.; Turka, L.A.; Hale, L.P.; Smith, P.A.; Schneider, M.A.; MacIver, N.J.; Locasale, J.W.; Newgard, C.B.; Shinohara, M.L.; Rathmell, J.C. (2014). Metabolic Programming and PDHK1 Control CD4 T-Cell Subsets and Inflammation, J. Clin. Inv. 125(1):194-207. [PDF] [Pubmed]
  40. Wood, K.B.; Wood, K.C.; Nishida, S.; Cluzel, P. (2014). Conservation laws for resistance to multi-drug treatments in microbes and human cancer cells, Cell Reports 6, 1073-84. [Pubmed] [PDF]
  41. Wood, K.C.; Konieczkowski, D.J.; Johannessen, C.M.; Boehm, J.S.; Tamayo, P.; Botvinnik, O.B.; Mesirov, J.P.; Hahn, W.C.; Root, D.E.; Garraway, L.A.; Sabatini, D.M. (2012). MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma, Science Signaling 5, rs4 (journal cover article). [Pubmed][PDF]
  42. Wood, K.C.; Azarin, S.M.; Arap, W.; Pasqualini, R.; Langer, R.; Hammond, P.T. (2008). Tumor-targeted gene delivery using molecularly engineered hybrid polymers functionalized with a tumor-homing peptide, Bioconjugate Chem. 19, 403-405. [Pubmed] [PDF]
  43. Wood, K.C.; Zacharia, N.S.; Schmidt, D.J.; Wrightman, S.; Andaya, B.J.; Hammond, P.T. (2008). Electroactive controlled release thin films, Proc. Natl. Acad. Sci. USA 105, 2280-2285. [Pubmed] [PDF]
  44. Wood, K.C.; Chuang, H.F.; Batten, R.D.; Lynn, D.M.; Hammond, P.T. (2006). Controlling interlayer diffusion to achieve sustained, multi-agent drug delivery from layer-by-layer thin films, Proc. Natl. Acad. Sci. USA 103, 10207-10212. [Pubmed] [PDF]
  45. Wood, K.C.; Little, S.R.; Langer R.; Hammond, P.T. (2005). A family of hierarchically self-assembling linear-dendritic hybrid polymers for targeted efficient gene delivery, Angew. Chem. Int. Ed. 44, 6704-6708. [Pubmed][PDF]
  46. Wood, K.C.; Boedicker, J.Q.; Lynn, D.M.; Hammond, P.T. (2005). Tunable drug release from hydrolytically degradable layer-by-layer thin films, Langmuir, 21, 1603-1609. [Pubmed] [PDF]
  47. Meyer, D.E.; Wood, K.; Bachas, L.G.; Bhattacharyya, D. (2004). Degradation of chlorinated organics by membrane-immobilized nanosized metals, Environ. Prog., 23, 232-242. [PDF]